In-Practice Evaluation of Atacand 16mg Antihypertensive Effect
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Hypertension
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Agrita Hartmane, Study Director, Affiliation: AstraZeneca
Overall contact:
AstraZeneca Latvia Clinical Study Information, Phone: +371 67377100, Email: agrita.hartmane@astrazeneca.com
Summary
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in
reducing blood pressure after 4 weeks of administration and the importance of administration
of adequate doses
Clinical Details
Official title: In-Practice Evaluation of Atacand 16mg Antihypertensive Effect
Study design: Case-Only, Prospective
Primary outcome: Decrease in blood pressure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg)
essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not
reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has
decid
- Signed and dated Patient Informed Consent (ICF)
Exclusion Criteria:
- Hypersensitivity to the active substance or to any of the excipients of Atacand.
Locations and Contacts
AstraZeneca Latvia Clinical Study Information, Phone: +371 67377100, Email: agrita.hartmane@astrazeneca.com
Research Site, Riga, Latvia; Recruiting
Research site, Liepaja, Latvia; Not yet recruiting
Research site, Daugavpils, Latvia; Not yet recruiting
Research site, Jelgava, Latvia; Not yet recruiting
Additional Information
Starting date: November 2008
Ending date: February 2009
Last updated: January 12, 2009
|
